LevelJump Announces 2025 Financial Results

Revenue is up, but losses persist and disclosure gaps limit investor confidence.

What the company is saying

LevelJump Healthcare Corp. positions itself as a growing healthcare provider focused on telehealth and in-person radiology, emphasizing its role in critical care for urgent and emergency patients. The company highlights a 7.9% year-over-year revenue increase to $19.1 million in 2025, framing this as a sign of operational strength and market demand. CEO Mitchell Geisler asserts that 2025 was a 'strong year' and claims the highest revenues in company history, though this is not substantiated with multi-year data. The announcement draws attention to the negative Q4 EBITDA, attributing it to one-off legal and ancillary costs from a shareholder requisition, and reassures investors that these costs are not expected to recur. The company is careful to present the annual EBITDA of $1,662,510 as evidence of underlying profitability, despite the annual net loss of $815,018. There is a clear effort to downplay the Q4 weakness and shift focus to the full-year results and the subsidiary's $3.84 million EBITDA. The messaging is neutral in tone, with a measured confidence that avoids overt hype but still seeks to reassure. No new business initiatives, financing activities, or strategic shifts are mentioned, and the company omits any discussion of cash flow, balance sheet health, or future guidance. The narrative fits a standard investor relations approach for a small-cap healthcare company: highlight top-line growth, explain away negative surprises as non-recurring, and avoid details that could raise further questions.

What the data suggests

The disclosed numbers show that LevelJump Healthcare Corp. generated $19.1 million in revenue for 2025, up from $17.7 million in 2024, confirming a 7.9% annual growth rate. The company’s 100% owned subsidiary, Canadian Teleradiology Services, Inc., reported EBITDA of $3.84 million for 2025, but the consolidated annual EBITDA is lower at $1,662,510, indicating that other business segments or corporate costs are significant. Q4 2025 revenue was $5.1 million, but EBITDA for the quarter was negative at $(105,000), and the company posted a net loss from operations of $815,018 for the year. The gap between the positive revenue growth narrative and the actual bottom line is notable: while revenues are rising, the company remains unprofitable on an operational basis. The claim that Q4 EBITDA was impacted by non-recurring legal costs is not supported by a detailed expense breakdown, making it difficult to assess whether this is a one-off or a symptom of deeper cost issues. The financial disclosures are clear for the periods presented but lack key metrics such as cash flow, gross margin, segment performance, and any balance sheet data, limiting a full assessment of financial health. There is no evidence of missed or met prior targets, as no guidance or historical targets are disclosed. An independent analyst would conclude that while the company is growing its top line, persistent losses and incomplete disclosures raise questions about the sustainability and quality of that growth.

Analysis

The announcement is primarily factual, reporting realised financial results for 2025, including revenue, EBITDA, and net loss figures. The only forward-looking claim is the assertion that legal and ancillary costs impacting Q4 EBITDA are not expected to recur, which is a minor projection and does not materially inflate the overall narrative. The CEO's statement that 2025 was a 'strong year' is positive in tone but is supported by the disclosed 7.9% revenue growth. However, the company still reported a net loss from operations, and the Q4 EBITDA was negative, which tempers the strength of the positive narrative. There is no evidence of capital-intensive projects or long-dated, uncertain returns; the results are for a completed period. The gap between narrative and evidence is minimal, with most claims directly supported by disclosed numbers.

Risk flags

• ●Operational risk is evident as the company remains unprofitable, with a net loss from operations of $815,018 in 2025 despite revenue growth. Persistent losses can erode cash reserves and limit strategic flexibility.
• ●Disclosure risk is significant: the company omits cash flow, gross margin, segment-level performance, and balance sheet data, making it difficult for investors to assess liquidity, solvency, or the sustainability of operations.
• ●Execution risk arises from the claim that Q4 legal and ancillary costs are non-recurring, yet no detailed breakdown is provided. If similar costs recur, future profitability could be further impaired.
• ●Pattern-based risk is present in the company's focus on explaining away negative Q4 EBITDA as a one-off event, which may mask underlying cost control or governance issues.
• ●Financial risk is underscored by the gap between positive EBITDA at the subsidiary level ($3.84 million) and much lower consolidated EBITDA ($1,662,510), suggesting that other business units or corporate overhead are dragging down overall performance.
• ●Forward-looking risk is moderate: while most claims are based on realised results, the assertion that legal costs will not recur is a forward-looking statement that cannot be verified until subsequent quarters are reported.
• ●Geographic risk is present as the company operates in both Ontario and the United States, but the announcement provides no detail on regional performance, regulatory exposure, or market-specific challenges.
• ●Leadership risk is low in terms of transparency, as CEO Mitchell Geisler is clearly identified, but there is no evidence of notable institutional investors or external validation, which could otherwise bolster confidence.

Bottom line

For investors, this announcement confirms that LevelJump Healthcare Corp. is growing revenues at a moderate pace, but it is still not profitable and key financial details are missing. The company’s narrative is credible in terms of reported revenue growth, but less so regarding the sustainability of profitability, given the persistent net loss and lack of transparency around costs. CEO Mitchell Geisler’s involvement signals continuity but does not provide any additional institutional credibility or external validation. To improve investor confidence, the company would need to disclose cash flow statements, gross margin data, segment-level results, and a detailed breakdown of extraordinary costs. In the next reporting period, investors should watch for evidence that legal and ancillary costs have indeed subsided, as well as any improvement in EBITDA and net income. The information here is worth monitoring, but not acting on, until more comprehensive disclosures are provided and operational profitability is demonstrated. The most important takeaway is that while revenue growth is positive, the company’s path to sustainable profitability remains unproven and opaque, and investors should demand greater transparency before considering a position.

Announcement summary

(TSXV: JUMP) LevelJump Healthcare Corp. announced its financial results for the year ended December 31, 2025, reporting revenues of $19.1 million in 2025 compared to $17.7 million in 2024, representing a year over year revenue increase of 7.9%. Canadian Teleradiology Services, Inc., the Company's 100% owned subsidiary, had EBITDA for 2025 of $3.84 million. Revenues for the fourth quarter of 2025 were $5.1 million, with a net loss from operations of $815,018 for the year 2025. EBITDA was $(105,000) for Q4 2025 and $1,662,510 for the year 2025. The company states that the dip in Q4 EBITDA was largely attributable to legal and ancillary costs associated with the shareholder requisition, which are not expected to recur. LevelJump Healthcare Corp. provides telehealth solutions to client hospitals and imaging centers through its Teleradiology division, as well as in person radiology services through its Diagnostic Centres. The company focuses primarily on critical care for urgent and emergency patients.

Disagree with this article?